Clinical trials: Viral Respiratory Illnesses
COVID-19
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
This is a Phase 1/2, randomized, double-blind, placebo-controlled, single-dose escalating-dose study in participants with mild to moderate COVID-19 illness.
- Trial name
- NCT05298813
- Testing
- IBIO123
- Where
- 11 sites in Brazil, South Africa
- Volunteers
- 162 people
- Sponsor
- Immune Biosolutions Inc
Healthy, Chronic Stable Illness
Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19
The primary objectives are: To assess the occurrence of adverse events of special interest (AESIs) in participants treated with repeated subcutaneous (SC) doses of REGN10933+REGN10987 compared to placebo To assess the…
- Trial name
- NCT04519437
- Testing
- REGN10933+REGN10987
- Where
- 7 sites in United States
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Respiratory Viral Infections, Respiratory Syncytial Virus Infections
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
The overall objective of the MEDI-534 clinical development program is to evaluate the safety, efficacy and tolerability of MEDI-534 for the prevention of serious RSV and PIV3 disease in young infants.
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Trial name
- CP149 (NCT00493285)
- Testing
- MEDI-534
- Where
- 30 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy, Chronic Stable Illness
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
The primary objective of the study is to assess the safety and tolerability of co-formulated subcutaneous (SC) and intravenous (IV) casirivimab+imdevimab The secondary objectives of the study are to: Explore variability in the…
- Trial name
- NCT05181683
- Testing
- Casirivimab+Imdevimab
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
COVID-19
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in…
- Trial name
- NCT07664696
- Testing
- IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- Volunteers
- 64 people
- Sponsor
- Kimera Labs Inc.
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2…
- Trial name
- NCT04359680
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 26 sites in United States
- Volunteers
- 1,407 people
- Sponsor
- Romark Laboratories L.C.
Healthy
Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children
This is a randomized, double-blind, placebo-controlled, dose-escalation, Phase 1, multi-center study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534 in healthy children 1-9 years of age who…
- Trial name
- NCT00345670
- Testing
- MEDI-534
- Where
- 12 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-4 (NCT04634409)
- Testing
- Bamlanivimab, Etesevimab, VIR-7831
- Where
- 141 sites in United States, Argentina and 1 more
- Volunteers
- 1,755 people
- Sponsor
- Eli Lilly and Company
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
Viral Respiratory Infection, Viral Respiratory Illnesses
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide.
- Trial name
- POSITS (NCT07222670)
- Testing
- INNA-051
- Where
- 6 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Influenza, Influenza A
Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI
The goal of this prospective, digital randomized controlled trial is to evaluate the effectiveness of a predictive ILI detection algorithm and associated alerts during influenza season for adults living in the contigent United…
- Conditions
- Influenza, Influenza A, Influenza B, COVID-19
- Trial name
- NCT06229444
- Testing
- ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content
- Where
- United States
- Volunteers
- 17,043 people, healthy volunteers welcome
- Sponsor
- Evidation Health
COVID-19
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
- Trial name
- NCT05011513
- Testing
- PF-07321332, Ritonavir
- Where
- 225 sites in United States, Argentina and 18 more
- Volunteers
- 1,440 people
- Sponsor
- Pfizer
COVID19
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Trial name
- NCT05175690
- Testing
- Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Acute Respiratory Viral Infection
A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness
The purpose of the study is to describe the rate of occurrence of clinical diagnosis of acute respiratory infection (an infection that affects normal breathing) and different types of respiratory pathogens (harmful organisms) of…
- Trial name
- BREEZE (NCT05661604)
- Testing
- No Intervention
- Where
- 4 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company